Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG
- PMID: 28102015
- PMCID: PMC5354965
- DOI: 10.1002/pros.23312
Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG
Abstract
Background: Few studies have considered etiological differences across molecular subtypes of prostate cancer, despite potential to improve opportunities for precision prevention of a disease for which modifiable risk factors have remained elusive. Factors that lead to DNA double-strand breaks, such as oxidative stress, may promote the formation of the TMPRSS2:ERG gene fusion in prostate cancer. We tested the hypothesis that increasing levels of pre-diagnostic circulating antioxidants, which may reduce oxidative stress, are associated with lower risk of developing TMPRSS2:ERG positive prostate cancer.
Methods: We conducted a nested case-control study, including 370 cases and 2,470 controls, to evaluate associations between pre-diagnostic α- and β-carotene, α- and γ-tocopherol, β-cryptoxanthin, lutein, lycopene, retinol, and selenium with the risk of prostate cancer by ERG protein expression status (a marker of TMPRSS2:ERG). Multivariable unconditional polytomous logistic regression was used to calculate odds ratios and 95% confidence intervals.
Results: We did not find any of the antioxidants to be significantly associated with the risk of prostate cancer according to ERG status.
Conclusions: The results do not support the hypothesis that circulating pre-diagnostic antioxidant levels protect against developing TMPRSS2:ERG positive prostate cancer. Additional studies are needed to explore mechanisms for the development of TMPRSS2:ERG positive disease. Prostate 77: 647-653, 2017. © 2017 Wiley Periodicals, Inc.
Keywords: biomarkers; epidemiology; molecular subtypes.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.Br J Cancer. 2016 Apr 12;114(8):939-44. doi: 10.1038/bjc.2016.61. Epub 2016 Mar 17. Br J Cancer. 2016. PMID: 26986253 Free PMC article.
-
A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.Eur Urol. 2019 Jul;76(1):33-40. doi: 10.1016/j.eururo.2018.09.041. Epub 2018 Oct 6. Eur Urol. 2019. PMID: 30301696 Free PMC article.
-
Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20. Prostate. 2013. PMID: 22821767
-
Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.Int J Cancer. 2025 May 15;156(10):1898-1908. doi: 10.1002/ijc.35279. Epub 2024 Dec 11. Int J Cancer. 2025. PMID: 39663641 Free PMC article.
-
The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.Dan Med J. 2016 Dec;63(12):B5319. Dan Med J. 2016. PMID: 27910803 Review.
Cited by
-
Serum Retinol and Risk of Overall and Site-Specific Cancer in the ATBC Study.Am J Epidemiol. 2020 Jun 1;189(6):532-542. doi: 10.1093/aje/kwz226. Am J Epidemiol. 2020. PMID: 31612201 Free PMC article. Clinical Trial.
-
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19.Semin Cancer Biol. 2022 Aug;83:384-398. doi: 10.1016/j.semcancer.2021.01.003. Epub 2021 Jan 20. Semin Cancer Biol. 2022. PMID: 33484868 Free PMC article. Review.
-
Selenium for preventing cancer.Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4. Cochrane Database Syst Rev. 2018. PMID: 29376219 Free PMC article.
-
Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary vascular disease.Food Sci Nutr. 2018 Aug 13;6(6):1770-1777. doi: 10.1002/fsn3.734. eCollection 2018 Sep. Food Sci Nutr. 2018. PMID: 30258622 Free PMC article.
-
Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.NPJ Precis Oncol. 2018 Jul 25;2:15. doi: 10.1038/s41698-018-0058-x. eCollection 2018. NPJ Precis Oncol. 2018. PMID: 30062144 Free PMC article. Review.
References
-
- Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448(7153):595–599. - PubMed
-
- Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet. 2010;11(12):819–829. - PubMed
-
- Mani RS, Amin MA, Li X, Kalyana-Sundaram S, Veeneman BA, Wang L, Ghosh A, Aslam A, Ramanand SG, Rabquer BJ, Kimura W, Tran M, Cao X, Roychowdhury S, Dhanasekaran SM, Palanisamy N, Sadek HA, Kapur P, Koch AE, Chinnaiyan AM. Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Rep. 2016;17(10):2620–2631. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical